Enteralia Team

The Leadership Team and Scientific Advisory Boards bring decades of experience as well as extensive expertise

A lean Leadership Team offers diverse yet complementary backgrounds and successful track records in specialty pharma.

We have strong scientific, R&D, medical, pharmaceutical, and commercial know-how bringing products to market. We have clear commitments to utilise cutting-edge science and technology to address unmet clinical needs. We have solid experience of starting, developing, growing, and divesting specialty pharma companies.

The Leadership Team is supported by our highly respected Scientific Advisory Board who provide specialist support. It is composed of a renowned network of scientists and clinicians from leading academic and health institutions.

Directors & Executive Management Team

Jeremy Buzzard

CEO

Jeremy has worked at the intersection of scientific innovation, business, strategy and M&A for the majority of his career, spanning small companies through to several of the largest healthcare companies in the world.
Jeremy has been an executive at the Danaher Corporation (NYSE: DHR), where he led business development for diagnostics, a C-suite member at several med-tech companies, and a partner at McKinsey, where he co-led the firms global healthcare strategy and corporate finance practices. During that time, he served clients evaluating more than $350Bn of potential transactions, including more than 25 major transactions that were executed with an aggregate value of $56Bn.
Jeremy has a PhD in cellular and molecular biology from Monash University, and has post-doctoral training in the same discipline from Harvard University.

Katelin Roberts

COO

Katelin has extensive experience both leading and investing in healthcare products companies (including as CEO), and managing innovation and complex operations across multiple industries in both the private and public sectors.
Most recently, Katelin helped found, and then lead BioHive, which is Utah’s collective of life sciences and healthcare innovation companies, focusing on building and accelerating Utah’s robust and growing life sciences industry.
Katelin is a partner in MedMountain Ventures, and serves on the boards of a number of medical technology companies and state government organizations. Katelin was recognized as one of Utah’s 40 under 40 in 2022.

Zachary Dutton

Corporate Development

Zachary (Zak) Dutton is a multifunctional healthcare professional and leader with over 20 years business and entrepreneurial experience with a focus on corporate development, partnerships and strategic planning. He has broad experience within healthcare and has held senior positions in multiple sectors including prescription drugs, medical foods and dietary supplements. He is the former CEO and founder of a US based pharmaceutical company that was acquired in 2019. Zak has held positions in multiple emerging companies in the healthcare field. He currently invests in and advises startup companies and is the member of several angel groups. He holds an Honors Bachelor of Arts from Queen’s University and received his MBA from the F.W. Olin School of Business at Babson College.

Max Kendall

CFO

Max has significant financial leadership experience delivering business growth, scale-up, optimisation and corporate transactions. Max joined the audit practice of Smith and Williamson, gaining broad industry experience, before joining Deloitte LLP (London) in 2007 where, as Director, Corporate Finance, he supported domestic and international clients achieve value accretive growth through transformational mergers, acquisitions and disposals, as well as fundraising and capital market transactions. Max now applies his expertise to driving growth of owner-led, entrepreneurial businesses.
Max is a graduate of Imperial College of Science, Technology and Medicine (BSc) and a certified Chartered Accountant (ACA).

Danilo Casadei Massari

Founder

Founder and CEO, Danilo has extensive experience as a senior pharmaceutical executive and as an entrepreneur. He was President and CEO of Fidia Pharmaceuticals, USA, and Director of International Corporate Development with Fidia Farmaceutici S.p.A. He also served as VP, Corporate Development at Madaus AG and held several senior management positions in several Pharma Companies. As a serial entrepreneur he has founded several pharmaceutical companies, including, CM&D Pharma Limited, a company focused on prescription Medical Foods, which was acquired by Nestle Health Science in 2011.

Maria Cristina Comelli

Director R&D

A passionate researcher into the relationship between epigenetics and nutrition. Her focus is the role that specific nutrients could exert in primary, and particularly in secondary, prevention of chronic diseases as functional adjuncts to medicinal products. Cristina has held senior R&D management positions in a number of European companies, is an inventor on numerous patents and often consults on regulatory affairs. She served as director in CM&D Pharma, acquired by Nestle Health Science. Cristina is a Member of the Board in ExPharma Limited, a UK based R&D Company.

Scientific Advisory Board

Dr. Margit Holzer

Scientific Director at Ulysse-Consult Sarl

Margit Holzer is a passionate biochemical engineer with internationally recognized expertise in development, industrialization and implementation of biotechnological production processes, in the field of pharma and food applications. She holds a master and a PhD in biotechnology from the University of Natural Resources and Applied Life Sciences in Vienna (Austria). Margit has worked all over Europe for Boehringer-Ingelheim and Novasep, she headed various positions in R&D, production, quality, technology and business including several worldwide executive ones. Since end of 2012 she serves the industry as an independent consultant at Ulysse-Consult. Amongst other achievements she has supervised product and process development of more than 60 different products, several of them reached market authorization.

Dr Carmen Gianfrani

Head of Mucosal Immunology Laboratory at the Institute of Biochemistry and Cell Biology – Italian National Council of Research

Dr Carmen Gianfrani is an immunologist, Head of Mucosal Immunology Laboratory at the Institute of Biochemistry and Cell Biology – Italian National Council of Research (IBBC - CNR). Her scientific interest is mainly focused on the pathogenesis of gluten related disorders and immunotherapies to restore oral tolerance to gluten proteins in Celiac Disease patients. She has also contributed to develop biochemical strategies detoxifying wheat gluten, that are currently in clinical trials. Dr Gianfrani is section editor of Pediatric Research and coordinator of Science Outreach Program at IBP CNR.

Dr Linda Cavaletti

Senior Associate Scientist at Fondazione Istituto Insubrico di Ricerca per la Vita

Linda Cavaletti is a biologist with long expertise in isolation and cultivation of strains for natural products discovery. Her professional carrer started in the Lepetit Research Center (then Biosearch Italia, then Vicuron Pharmaceuticals), where she could discover new microbial taxa, including previously uncultivated strains. Since 2008, she joined FIIRV focusing her activity on the generation of a FIIRV proprietary strain library. After diagnoses concerning family members, she developed a deep interest in celiac disease and its pathogenesis, culminating in a project for discovery of a new glutenase by acidophilic actinomycete strains. Since that time, she is leader of the Celiac Disease project in FIIRV, which led to discovery of E40, and its patenting in 2011. Since 2017, she collaborates with Nemysis for E40 development.